| Ticker代號 | Day %當日% | Category分類 | Catalyst催化 |
|---|---|---|---|
| ON M&A · vol 43.6M · 🔬 deep dive深挖 | -23.7% | 🚀 EP | ON Semiconductor plunged as its ~$7 billion acquisition of Synaptics drew investor questions over price and strategic fit.安森美因約 70 億美元收購 Synaptics 案遭投資人質疑價格與策略綜效而重挫。 ⚠ Deal previously announced; today's -24% is the market repricing the $7B Synaptics acquisition on price/strategic-fit concerns.併購案先前已宣布;今日 -24% 是市場對 70 億美元收購 Synaptics 的價格與綜效疑慮重新定價。 source新聞↗
|
| FCEL Contract · vol 26.7M · 🔬 deep dive深挖 | +22.1% | 🚀 EP | FuelCell Energy surged after landing a 380 MW data-center power deal with Fit Energy, with UBS tripling its price target.FuelCell Energy 因拿下與 Fit Energy 的 380 百萬瓦資料中心供電案、加上 UBS 將目標價調高三倍而大漲。 ⚠ UBS tripled its price target alongside the deal; MW scale given, dollar terms undisclosed.UBS 同步將目標價調高三倍;公布百萬瓦規模,但金額未揭露。 source新聞↗
|
| OMER Reg · vol 10.5M · 🔬 deep dive深挖 | -19.1% | 🚀 EP ★ MAGNA | Omeros dropped after the EMA's CHMP issued a negative opinion on Yartemlea (narsoplimab), jeopardizing its European approval.Omeros 因 EMA 的 CHMP 對 Yartemlea(narsoplimab)發出負面意見、危及其歐洲上市而下跌。 ⚠ Negative opinion, not final; EMA gave 15 days to request a re-examination.為負面意見而非最終決定;EMA 給予 15 天可申請重新審查。 source新聞↗ |
| Ticker代號 | Day %當日% | Category分類 | Catalyst催化 |
|---|---|---|---|
| MRNA Product · vol 14.3M · 🔬 deep dive深挖 | +12.6% | 🔥 SIP ★ MAGNA | Moderna rose after its investor day, where it touted a new R&D push including an autoimmune-disease program.Moderna 在投資人日上主打包括自體免疫疾病在內的新研發方向後上漲。 ⚠ Driver is the investor-day narrative + early autoimmune R&D, not a hard approval/contract; Sales q/q swing is largely seasonal.推動力為投資人日題材與早期自體免疫研發,而非確定核准或合約;營收季增主要為季節性。 source新聞↗
|
| DKNG Product · vol 16.5M · 🔬 deep dive深挖 | +11.3% | 🔥 SIP ★ MAGNA | DraftKings rose after launching a prediction-markets (event-contract) exchange, entering a fast-growing new category.DraftKings 因推出預測市場(事件合約)交易所、進軍快速成長的新領域而上漲。 ⚠ New-vertical launch into prediction markets; revenue contribution unproven.進軍預測市場的新業務線上線;營收貢獻尚未證實。 source新聞↗
|
| FRMI Contract · vol 27.4M · 🔬 deep dive深挖 | +7.8% | 🔥 SIP | Fermi selected Spain's TSK as the EPC contractor for early-works engineering on three Siemens gas turbines for the second phase of its Project Matador power campus in Texas.Fermi 選定西班牙 TSK 為 EPC 承包商，負責德州 Project Matador 第二期三台 Siemens 燃氣渦輪的前期工程設計。 ⚠ Early-works engineering agreement (Fermi is hiring the EPC, not winning revenue) — project de-risking, not committed sales; stock has also been running on OpenAI buzz.前期工程設計協議（Fermi 是發包方、非取得營收）—專案降風險而非確定營收；股價近期也受 OpenAI 話題推動。 source新聞↗
|
| IBM Product · vol 9.3M · 🔬 deep dive深挖 | +5.0% | 🔥 SIP | IBM unveiled what it called the world's first sub-1nm chip technology, packing nearly 100 billion transistors onto a fingernail-sized chip, with production estimated as early as five years out.IBM 發表其稱為全球首款的次 1 奈米晶片技術,在指甲大小的晶片上集成近千億顆電晶體,預計最快五年後可量產。 ⚠ Production estimated as early as 5 years out — a tech milestone, not near-term revenue; also rode a JPMorgan upgrade to Overweight this week.量產預計最快還要五年——是技術里程碑而非近期營收;本週另有摩根大通升評至加碼加持。 source新聞↗
|
| REPL Reg · vol 9.9M · 🔬 deep dive深挖 | +4.5% | 🔥 SIP | The FDA accepted Replimune's resubmitted Biologics License Application for RP1 in advanced melanoma.FDA 受理了 Replimune 針對晚期黑色素瘤 RP1 的生物製劑許可申請(BLA)重新申報。 ⚠ FDA ACCEPTANCE of a resubmission means the agency agreed to review — a de-risking step, NOT an approval; a PDUFA decision is still pending. The +10% on 06-22 was the resubmission-plan news; today is the formal acceptance.FDA「受理」重新申報代表同意審查——是去風險步驟,並非核准;PDUFA 決定仍待公布。06-22 的 +10% 是重新申報計畫消息,今天是正式受理。 source新聞↗ |
| Ticker代號 | Day %當日% | Category分類 | Catalyst催化 |
|---|---|---|---|
| BB Analyst · vol 55.4M | +10.3% | 🟡 Bounce ★ MAGNA | BlackBerry extended its post-earnings rally as TD and CIBC raised price targets following its upbeat Q1 results.BlackBerry 延續財報後漲勢,TD 與 CIBC 在亮眼的 Q1 業績後調高目標價。 ⚠ Day-2 extension of the +20% earnings-day pop; today's driver is TD/CIBC price-target raises, not fresh news.為財報日 +20% 後的第二天延續;今日推力是 TD 與 CIBC 調高目標價,非新催化。 source新聞↗
|
| RKLB Contract · vol 33.0M | +4.8% | 🟡 Bounce | Rocket Lab rebounded after a steep multi-day slide, having completed its 10th consecutive successful launch (for Synspective) and been selected by NASA for three Electron launches.Rocket Lab 在連日重挫後反彈,期間完成第十次連續成功發射(為 Synspective),並獲 NASA 選定執行三次 Electron 發射任務。 ⚠ Today is a rebound after a ~-25% multi-session slide and a space-name re-rotation (VG +13%, ASTS +9%); the launch is routine ops and the NASA selection is incremental — not a fresh pivot.今天是連跌約 -25% 數個交易日後的反彈,並伴隨太空股輪動(VG +13%、ASTS +9%);發射屬例行作業、NASA 入選屬增量——非全新催化轉折。 source新聞↗
|
| TNGX Clinical · vol 13.8M | +4.4% | 🟡 Bounce | Tango rose on read-through from partner Revolution Medicines' positive Phase 3 pancreatic-cancer data, since daraxonrasib is being studied in combination with Tango's vopimetostat.Tango 因合作夥伴 Revolution Medicines 公布利多的三期胰臟癌數據而受惠上漲——daraxonrasib 正與 Tango 的 vopimetostat 進行合併用藥試驗。 ⚠ Read-through, not Tango's own readout: today's Phase 3 data belongs to PARTNER Revolution Medicines; Tango's vopimetostat is only a combination agent in the regimen. A sympathy/read-through move.是讀通效應而非 Tango 自家數據:今天的三期數據屬合作夥伴 Revolution Medicines;Tango 的 vopimetostat 僅為該療法中的合併用藥,屬同向/讀通行情。 source新聞↗ |
| FISV Legal · vol 16.7M | +4.0% | 🟡 Bounce | Fiserv rose near 52-week lows as insiders bought stock following the CEO's exit and activist Jana Partners nearly doubled its stake.Fiserv 在接近 52 週低點之際上漲,因執行長離任後內部人買進股票,且行動派 Jana Partners 將其持股近乎加倍。 ⚠ Sentiment/governance bounce near a 52-week low: insiders buying after the CEO's exit and activist Jana Partners nearly doubling its stake; the €1B euro-note issuance funds routine debt refinancing, not growth.近 52 週低點的情緒/治理反彈:執行長離任後內部人買進、行動派 Jana Partners 將持股近乎加倍;10 億歐元發債用於例行債務再融資,非成長性用途。 source新聞↗ |